Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | September 12, 2024 | September 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date September 12, 2024 · Filed September 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 17,443 |
Reported balance
After 2024-09-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-09-12 · Purchase · Acquired 6,000 · Balance 17,443 F1: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. |
| Common StockSEC Table I · non-derivative | Direct | 12,257 |
Reported balance
Holding disclosure · report date 2024-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,257 |
| Common StockSEC Table I · non-derivative | IndirectBy Adult Child 1 | 3,040 |
Reported balance
Holding disclosure · report date 2024-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,040 F2: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Adult Child 2 | 2,840 |
Reported balance
Holding disclosure · report date 2024-09-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,840 F3: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Adult Child 3 | 2,650 |
Reported balance
Holding disclosure · report date 2024-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,650 F4: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price.
F2: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2024 Filed Sep 16, 2024 18:53 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,000 | $6.47 | $38,814.00 |
DisclosureSEC source: 0001493152-24-036461 · ownership.xml · nonDerivative · entry 1 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 17,443 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 18:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 2,650 | $6.59 | $17,461.65 |
DisclosureSEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 5 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adult Child 3 Disclosed balance after: 2,650 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. F4 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 18:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,600 | $6.59 | $10,542.88 |
DisclosureSEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 4 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adult Child 2 Disclosed balance after: 2,840 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. F3 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 18:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,800 | $6.59 | $11,860.74 |
DisclosureSEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 3 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adult Child 1 Disclosed balance after: 3,040 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. F2 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 18:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,543 | $6.59 | $10,167.29 |
DisclosureSEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 2 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 11,443 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 18:55 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,350 | $6.59 | $8,895.56 |
DisclosureSEC source: 0001493152-24-033195 · ownership.xml · nonDerivative · entry 1 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,257 F1 · price: The price reflects the weighted average purchase price of multiple transactions. Upon the written request of the SEC, the issuer or a security holder of the issuer, the Reporting Person agrees to provide the number of shares sold at each sale price. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:26 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 2,600 | $9.00 | $23,400.00 |
DisclosureSEC source: 0001493152-24-025498 · ownership.xml · nonDerivative · entry 2 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,907 Read SEC document |
| June 21, 2024 Filed Jun 27, 2024 20:26 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 5,000 | $9.50 | $47,500.00 |
DisclosureSEC source: 0001493152-24-025498 · ownership.xml · nonDerivative · entry 1 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,307 Read SEC document |
| May 21, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 2,500 | $9.75 | $24,375.00 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 4 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,900 Read SEC document |
| May 21, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 6,651 | $10.00 | $66,510.00 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 3 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,400 Read SEC document |
| May 20, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,240 | $9.42 | $11,683.28 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 6 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adult Child 2 Disclosed balance after: 1,240 F2 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 20, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 1,240 | $9.44 | $11,701.88 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 5 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Adult Child 1 Disclosed balance after: 1,240 F1 · ownership.nature: The Reporting Person may be deemed to share voting, investment and dispositive power with respect to these securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 20, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 195 | $9.48 | $1,848.02 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 2 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 749 Read SEC document |
| May 17, 2024 Filed May 23, 2024 17:07 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 554 | $8.50 | $4,709.00 |
DisclosureSEC source: 0001493152-24-021176 · ownership.xml · nonDerivative · entry 1 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 554 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001493152-24-013087 · ownership.xml · derivative · entry 1 MINTZ STEVEN · CIK 0002008741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,812 Underlying: Common Stock · 40,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · balance_after: Number of derivative securities determined after giving effect to a reverse split of the Issuer's common stock of 1-for-35.17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.